



Metropolitan Stock Exchange of India Limited

Department: Investigation

Segment: All

Circular No: MSE/ID/7892/2019

Date : July 10, 2019

SEBI Order in the matter of Celestial Biolabs Limited (CBL)

To All Members,

This is with reference to the Exchange circular no: MSE/ID/6873/2018 dated October 08, 2018 regarding SEBI order no WTM/MPB/EFD-1-DRA-III/46/2018 dated October 05, 2018 in respect of Celestial Biolabs Limited (CBL).

SEBI now vide Order no WTM/MPB/EFD-1-DRA-III/56/2019 dated July 10, 2019, has issued, the following directions, for below mentioned entities:-

Sr No.	Name of the Entities	PAN	CIN/DIN
1	Celestial Biolabs Ltd.	AABCC4698Q	L72200TG1997PLCO28374
2	Dr. Aditya Narayan Singh	AITPS2152A	01756827
3	Ms. Padma Singh	BIQPS8097A	01448915

- a) CBL shall not buy, sell or otherwise deal in the securities market in any manner whatsoever or access the securities market, directly or indirectly, for a period of 5 years from the date of this order. However, CBL is permitted to raise the money for the on-going project / expansion plans at Genome Valley, Hyderabad covered in the brochure/Information memorandum submitted to SEBI by way of preferential allotment to Qualified Institutional Buyers / Alternative Investment Funds as defined under the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009 / Securities and Exchange Board of India (Alternative Investment Funds) Regulations, 2012 as amended from time to time. It is clarified that CBL is prohibited to raise the money from any other investors in any other manner. CBL shall file a report of such raising of money from Qualified Institutional Buyers / Alternative Investment Funds to the Stock Exchanges where the shares of CBL are listed. For the calculation of five years period, the period of debarment already undergone by CBL from the date of earlier order dated October 5, 2018 shall be deducted from the five years period.
- b) Dr. A.N. Singh and Ms. Padma Singh shall not buy, sell or otherwise deal in the securities market in any manner whatsoever or access the securities market, directly or indirectly, for a period of 5 years from the date of this order. However for the on-going project / expansion plans at Genome Valley, Hyderabad, Dr. A.N. Singh and Ms. Padma Singh are permitted to subscribe to equity or debt capital of CBL along with Qualified Institutional Buyers / Alternative Investment Funds, for the above said project. For the calculation of five years period, the period of debarment already undergone by Dr. A.N. Singh and Ms. Padma Singh from the date of earlier order dated October 5, 2018 shall be deducted from the five years period.
- c) Further, Dr. A.N. Singh and Ms. Padma Singh are also restrained from associating themselves with any listed public company other than CBL or any public company which intends to raise money from the public, or any intermediary registered with SEBI for a period of 5 years from the date of this order. For the calculation of five years period, the period restraint already undergone by Dr. A.N.

Singh and Ms. Padma Singh from the date of earlier order dated October 5, 2018 shall be deducted from the five years period.

It may be noted that in light of the directions issued in this order, the directions issued against CBL and Dr. A.N. Singh and Ms. Padma Singh in the earlier order dated October 5, 2018 as modified herein shall be applicable.

Members of the Exchange are advised to take note of the full text of the order available on SEBI's website [www.sebi.gov.in] and ensure compliance.

**For and on behalf of
Metropolitan Stock Exchange of India Limited**

Prachi Lendhe
Assistant Vice President